Valuation: Nexstim Plc

Market Cap 79.3M 90.65M 73.14M 67.55M 128M 8.65B 130M 874M 343M 4.26B 340M 333M 14.64B P/E 2026 *
81.8x
P/E 2027 * 36.4x
Enterprise Value 77.2M 88.25M 71.2M 65.76M 125M 8.42B 127M 851M 334M 4.15B 331M 324M 14.25B EV / Sales 2026 *
6.08x
EV / Sales 2027 * 4.7x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 2020-02-10
Director of Finance/CFO 40 2020-02-10
Chief Tech/Sci/R&D Officer 65 2007-12-31
Director TitleAgeSince
Director/Board Member 64 2019-11-10
Chairman 63 2019-11-10
Director/Board Member 55 2021-04-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 90.65M
+0.45%+0.69%+22.36%+1.97% 196B
-1.16%-4.51%-22.67%+19.55% 144B
+1.57%+0.57%-3.14%-15.11% 141B
-0.49%-0.82%-56.89%-15.05% 66.54B
+0.96%-2.29%+17.02%+0.62% 53.09B
+0.61%-1.09%-27.71%-30.42% 44.12B
+0.52%+2.75%+8.15%+13.46% 37.93B
-0.19%-0.75%+6.55%+42.23% 36.96B
-2.20%-2.75%-21.00%-5.88% 29.41B
Average +0.41%-1.00%-8.59%+1.26% 83.21B
Weighted average by Cap. +0.74%-1.02%-4.67%+0.88%

Financials

2026 *2027 *
Net sales 12.7M 14.52M 11.71M 10.82M 20.53M 1.38B 20.87M 140M 54.96M 682M 54.52M 53.33M 2.35B 16.1M 18.41M 14.85M 13.72M 26.03M 1.76B 26.46M 177M 69.68M 865M 69.11M 67.61M 2.97B
Net income 1M 1.14M 922K 852K 1.62M 109M 1.64M 11.02M 4.33M 53.71M 4.29M 4.2M 185M 2.2M 2.52M 2.03M 1.87M 3.56M 240M 3.62M 24.25M 9.52M 118M 9.44M 9.24M 406M
Net Debt -2.1M -2.4M -1.94M -1.79M -3.39M -229M -3.45M -23.14M -9.09M -113M -9.01M -8.82M -388M -3.7M -4.23M -3.41M -3.15M -5.98M -403M -6.08M -40.78M -16.01M -199M -15.88M -15.54M -683M
Logo Nexstim Plc
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
40
Trader
Investor
Global
Quality
ESG MSCI
-